WO2002024923A1 - Polypeptide ayant une activite phospholypase a¿2? - Google Patents

Polypeptide ayant une activite phospholypase a¿2? Download PDF

Info

Publication number
WO2002024923A1
WO2002024923A1 PCT/JP2001/008138 JP0108138W WO0224923A1 WO 2002024923 A1 WO2002024923 A1 WO 2002024923A1 JP 0108138 W JP0108138 W JP 0108138W WO 0224923 A1 WO0224923 A1 WO 0224923A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
phospholipase
inhibitory
vector
dna encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/008138
Other languages
English (en)
French (fr)
Inventor
Hiromasa Miyaji
Motoko Haruoka
Hiroyuki Nagata
Toshio Ota
Ayako Kawabata
Sumio Sugano
Yusuke Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to EP01970146A priority Critical patent/EP1329511A4/en
Priority to AU2001290240A priority patent/AU2001290240A1/en
Priority to CA002423058A priority patent/CA2423058A1/en
Priority to JP2002529515A priority patent/JPWO2002024923A1/ja
Priority to US10/380,873 priority patent/US7258855B2/en
Publication of WO2002024923A1 publication Critical patent/WO2002024923A1/ja
Anticipated expiration legal-status Critical
Priority to US11/829,510 priority patent/US20080044425A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
PCT/JP2001/008138 2000-09-19 2001-09-19 Polypeptide ayant une activite phospholypase a¿2? Ceased WO2002024923A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01970146A EP1329511A4 (en) 2000-09-19 2001-09-19 POLYPEPTIDE WITH PHOSPHOLIPASE A2 ACTIVITY
AU2001290240A AU2001290240A1 (en) 2000-09-19 2001-09-19 Polypeptide having phospholipase a2 actiivty
CA002423058A CA2423058A1 (en) 2000-09-19 2001-09-19 Polypeptide having phospholipase a2 activity
JP2002529515A JPWO2002024923A1 (ja) 2000-09-19 2001-09-19 ホスホリパーゼａ２活性を有するポリペプチド
US10/380,873 US7258855B2 (en) 2000-09-19 2001-09-19 Polypeptides having phospholipase A2 activity
US11/829,510 US20080044425A1 (en) 2000-09-19 2007-07-27 Polypeptides having phospholipase a2 activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000-284044 2000-09-19
JP2000284044 2000-09-19
JP2001-146466 2001-05-16
JP2001146466 2001-05-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/829,510 Division US20080044425A1 (en) 2000-09-19 2007-07-27 Polypeptides having phospholipase a2 activity

Publications (1)

Publication Number Publication Date
WO2002024923A1 true WO2002024923A1 (fr) 2002-03-28

Family

ID=26600245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008138 Ceased WO2002024923A1 (fr) 2000-09-19 2001-09-19 Polypeptide ayant une activite phospholypase a¿2?

Country Status (6)

Country Link
US (2) US7258855B2 (ja)
EP (1) EP1329511A4 (ja)
JP (1) JPWO2002024923A1 (ja)
AU (1) AU2001290240A1 (ja)
CA (1) CA2423058A1 (ja)
WO (1) WO2002024923A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076935A1 (fr) * 2002-03-14 2003-09-18 Kyowa Hakko Kogyo Co., Ltd. Preventifs ou remedes contre la dermatite
JP2006517193A (ja) * 2002-06-07 2006-07-20 キャラン・フランシス・スコット 前立腺ガン細胞の増殖の阻害方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2676321C1 (ru) * 2018-03-07 2018-12-27 Общество с ограниченной ответственностью "Инновационный центр "Бирюч-новые технологии" (ООО "ИЦ "Бирюч-НТ") Способ получения ферментного препарата фосфолипазы А2 с применением рекомбинантного штамма-продуцента Pichia pastoris X-33/ pPICZαA-PhoA2-StV

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025178A (en) * 1997-03-28 2000-02-15 Eli Lilly And Company Human phospholipase A2 and related nucleic acid compounds
WO2000024911A2 (en) * 1998-10-27 2000-05-04 Incyte Pharmaceuticals, Inc. Human phospholipases
WO2000047763A1 (en) * 1999-02-15 2000-08-17 Genetics Institute, Inc. CRYSTAL STRUCTURE OF cPLA2, AND METHODS OF IDENTIFYING AGONISTS AND ANTAGONISTS USING SAME

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053455A2 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001053326A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Methods and materials relating to phospholipase-like polypeptides and polynucleotides
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
US20040029136A1 (en) * 2001-07-06 2004-02-12 Tang Y. Tom Lipid metabolism molecules
CA2414219A1 (en) * 2000-07-07 2002-01-17 Incyte Genomics, Inc. Lipid metabolism molecules
WO2002031125A2 (en) 2000-10-10 2002-04-18 Bayer Aktiengesellschaft Human phospholipase a2-like enzyme

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025178A (en) * 1997-03-28 2000-02-15 Eli Lilly And Company Human phospholipase A2 and related nucleic acid compounds
WO2000024911A2 (en) * 1998-10-27 2000-05-04 Incyte Pharmaceuticals, Inc. Human phospholipases
WO2000047763A1 (en) * 1999-02-15 2000-08-17 Genetics Institute, Inc. CRYSTAL STRUCTURE OF cPLA2, AND METHODS OF IDENTIFYING AGONISTS AND ANTAGONISTS USING SAME

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076935A1 (fr) * 2002-03-14 2003-09-18 Kyowa Hakko Kogyo Co., Ltd. Preventifs ou remedes contre la dermatite
JP2006517193A (ja) * 2002-06-07 2006-07-20 キャラン・フランシス・スコット 前立腺ガン細胞の増殖の阻害方法
US7919458B2 (en) 2002-06-07 2011-04-05 Scott, Kieran, Francis Method of inhibiting prostate cancer cell proliferation

Also Published As

Publication number Publication date
EP1329511A4 (en) 2005-01-19
EP1329511A1 (en) 2003-07-23
AU2001290240A1 (en) 2002-04-02
US20080044425A1 (en) 2008-02-21
US20040014089A1 (en) 2004-01-22
CA2423058A1 (en) 2003-03-19
US7258855B2 (en) 2007-08-21
JPWO2002024923A1 (ja) 2004-01-29

Similar Documents

Publication Publication Date Title
WO2003062375A3 (en) Stabilizing polypeptides which have been exposed to urea
WO2005018572A3 (en) Improved antibodies having altered effector function and methods for making the same
WO2005047512A3 (en) Plasmid system for multigene expression
IL182716A0 (en) Method for purifying fsh
WO2003068959A1 (fr) Nouveau procede de criblage
WO2005023778A3 (en) Process for preparation of rosuvastatin calcium
WO2002084286A1 (en) Screening method
PL1664108T3 (pl) Rozdzielanie polipeptydów zawierających racemizowany aminokwas
WO2004048517A3 (en) Method for reducing or preventing modification of a polypeptide in solution
WO2004043403A3 (en) Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
WO2003072602A3 (en) Protein complexes and methods for their use
WO2006020001A3 (en) Fast multi-pass partitioning via priority based scheduling
WO2002024923A1 (fr) Polypeptide ayant une activite phospholypase a¿2?
AU5722499A (en) G protein-coupled receptor agonists or antagonists
WO2005042717A3 (en) Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods
WO2002000719A3 (en) Human and mouse g-protein couipled receptors
WO2003021262A1 (fr) Procede de criblage
WO2004007672A3 (en) Methods and materials relating to novel polypeptides and polynucleotides
WO2023177356A3 (en) Compounds and method for pkmyt1 inhibition
EP1365023A4 (en) DNA CODING A NOVEL D-AMINOACYLASE AND PROCESS FOR PRODUCING D-AMINOACID USING THE SAME
EP1677739A4 (en) METHODS FOR IDENTIFYING AGENTS THAT INHIBIT THE GROWTH OF CANCER CELLS
EP1338608A3 (en) Protein complexes and methods for their use
WO2000047723A3 (en) Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same
WO2003082320A1 (fr) Nouveau procede de criblage
WO2002057497A3 (en) High through-put cloning of protooncogenes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002529515

Country of ref document: JP

Ref document number: 10380873

Country of ref document: US

Ref document number: 2423058

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001970146

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001970146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642